Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus tiragolumab with chemoradiotherapy for localized anal canal squamous cell carcinoma
2023-509485-38-00Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and tiragolumab in anal squamous cell carcinoma (SCCA), sponsored by GEMCAD. Primary endpoint: Clinical complete response rate. Started Mar 2023; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2023-509485-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509485-38-00.